Short description of clinical study: Non-Interventional Study for Analysis of Molecular Diagnostics and Treatment Patterns in Metastatic Non-Small Cell Lung Cancer Patients (Newly Diagnosed and Relapses from Earlier Stages)
Countries: Bulgaria, Greece
Number of Sites: 5
Total number of processed patients: 233,985
Total number of eligible patients identified through the algorithm for minutes: 510
- 126 patients with EGFR tumour mutation
- 384 patients with PDL-1 expression
Total number of patients successfully enrolled in the clinical trial: 250
- 120 patients with EGFR tumour mutation
- 130 with PDL-1 expression
Benefits for Investigators and Sponsors:
- Enhanced Efficiency
- Accelerated Patient Enrolment
- Fast integration of Danny Platform with the sponsor’s eCRF ensures seamless data exchange, expediting trial management process and enhancing overall study efficiency
Why Danny eClinical Research:
The post Lung Real-World Evidence Secondary Use Study appeared first on Sqilline.
